

NOR-TEST 2 Part A

TNK in acute stroke

Norwegian Tenecteplase Stroke Trial

Kvistad CE Lancet neurol 2022

Inclusion

- Pre-stroke mRS ≤ 2 (independent)
- Admission NIHSS ≥ 6 (moderate-severe stroke)
- Treatment < 4.5 hours (standard criteria and wake-up stroke)

Treatment

- Tenecteplase 0.4 mg/kg vs. alteplase 0.9 mg/kg randomized 1:1

Included

- 216 patients

Safety analysis (per protocol)

- TNK \rightarrow higher bleeding rate and worse clinical outcome

Conclusion


- TNK 0.4 mg/kg is not recommended for moderate to severe stroke

Intracerebral bleedings


NOR-TEST 2 Part A

Norwegian Tenecteplase Stroke Trial
Kvistad CE Lancet neurol 2022

Intention-to-treat analysis / n=204



Any ICH




Symptomatic ICH

Outcome at 3 months


NOR-TEST 2 Part A

Norwegian Tenecteplase Stroke Trial
Kvistad CE Lancet neurol 2022

A Intention-to-treat analysis



B Per-protocol analysis



modified Rankin Scale

